[This corrects the article DOI: 10.1371/journal.pone.0222658.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970364 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266625 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system.
The Underutilization of Urea in the Treatment of SIADH - An Efficacious but Overlooked Solution.
Cureus
November 2024
Anaesthesia, Dow Health Sciences Karachi, Karachi, PAK.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a frequent cause of hyponatremia that presents substantial management challenges in clinical settings. Despite a range of treatment options, including fluid restriction, demeclocycline, and vasopressin antagonists, urea remains underutilized, particularly in North America, despite its well-documented efficacy, safety, and cost-effectiveness. Urea corrects hyponatremia by promoting osmotic diuresis without causing significant fluid shifts, making it an ideal treatment for both acute and chronic SIADH.
View Article and Find Full Text PDFIn brain-computer interfaces (BCIs) based on motor imagery (MI), reducing calibration time is gradually becoming an urgent issue in practical applications. Recently, transfer learning (TL) has demonstrated its effectiveness in reducing calibration time in MI-BCI. However, the different data distribution of subjects greatly affects the application effect of TL in MI-BCI.
View Article and Find Full Text PDFCytotoxicity assays for cancer drug screening: methodological insights and considerations for reliable assessment in drug discovery.
Braz J Biol
December 2024
Universiti Malaysia Terengganu, Institute of Climate Adaptation and Marine Biotechnology, Kuala Terengganu, Malaysia.
The importance of cytotoxicity assays in in vitro drug discovery investigations has led to their rising profile. Drugs and other substances can disrupt cell membranes, limit protein synthesis, and bind irreversibly to receptors, all of which lead to cell death in cancer cells. To precisely measure the cell death resulting from these damages, one must choose a cytotoxicity test that meets specific criteria.
View Article and Find Full Text PDFSTABLE trial of spectacle provision and driving safety among myopic motorcycle users in Vietnam: study protocol for a stepped-wedge, cluster randomised trial.
Trials
December 2024
Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, BT12 6BA, UK.
Background: Traffic crashes are the leading cause of death globally for people aged 5-29 years, with 90% of mortality occurring in low- and middle-income countries (LMICs). The STABLE (Slashing Two-wheeled Accidents by Leveraging Eyecare) trial was designed to determine whether providing spectacles could reduce risk among young myopic motorcycle users in Vietnam.
Methods: This investigator-masked, stepped-wedge, cluster randomised naturalistic driving trial will recruit 625 students aged 18-23 years, driving ≥ 50 km/week, with ≥ 1-year driving experience and using motorcycles as their primary means of transport, in 25 clusters of 25 students in Ho Chi Minh City, Vietnam.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!